A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
Clinical trial NCT05030506 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05030506
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-13
- Primary completion
- 2027-06-30
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.